1. Home
  2. PRME vs BLND Comparison

PRME vs BLND Comparison

Compare PRME & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

N/A

Current Price

$3.23

Market Cap

553.2M

Sector

Health Care

ML Signal

N/A

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.48

Market Cap

352.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
BLND
Founded
2019
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
553.2M
352.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
PRME
BLND
Price
$3.23
$1.48
Analyst Decision
Buy
Buy
Analyst Count
6
6
Target Price
$7.56
$4.13
AVG Volume (30 Days)
2.5M
2.5M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
58.33
EPS
N/A
N/A
Revenue
$4,632,000.00
$123,585,000.00
Revenue This Year
$7.06
$12.62
Revenue Next Year
$47.01
$14.00
P/E Ratio
N/A
N/A
Revenue Growth
55.28
N/A
52 Week Low
$2.67
$1.18
52 Week High
$6.94
$4.49

Technical Indicators

Market Signals
Indicator
PRME
BLND
Relative Strength Index (RSI) 51.43 40.37
Support Level $3.16 $1.38
Resistance Level $3.32 $1.67
Average True Range (ATR) 0.20 0.13
MACD 0.04 -0.03
Stochastic Oscillator 60.80 13.19

Price Performance

Historical Comparison
PRME
BLND

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.

Share on Social Networks: